Evidence map›Paper›PMID 25374256›Full record

Trial reportEuropean journal of drug metabolism and pharmacokinetics2016

CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect.

Xavier Boulenc, Olivier Nicolas, Stéphanie Hermabessière, Isabelle Zobouyan, Valérie Martin, Yves Donazzolo, Céline Ollier

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of drug metabolism and pharmacokinetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Exploring the Therapeutic Potential ofMolecules (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xavier BoulencDrug Disposition Domain, Disposition Safety and Animal Research, Sanofi, 371 rue du Professeur J. Blayac, 34184, Montpellier Cedex 04, France. xavier.boulenc@sanofi.com.
Olivier NicolasDrug Disposition Domain, Disposition Safety and Animal Research, Sanofi, 371 rue du Professeur J. Blayac, 34184, Montpellier Cedex 04, France.
Stéphanie HermabessièreClinical and Exploratory Pharmacology, Sanofi, Montpellier, France.
Isabelle ZobouyanClinical Documentation, Sanofi, Montpellier, France.
Valérie MartinBiostatistics, Sanofi, Chilly-Mazarin, France.
Yves DonazzoloEurofins Optimed, Lyon, France.
Céline OllierDrug Disposition Domain, Disposition Safety and Animal Research, Sanofi, 371 rue du Professeur J. Blayac, 34184, Montpellier Cedex 04, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the study was to assess the magnitude of the CYP3A4 inhibitory effect of 2 dosing regimens of ketoconazole and the influence of the pharmacokinetic properties of the CYP3A4 substrate on the extent of the substrate exposure increase. For this purpose, a clinical study was conducted and PBPK modeling simulations were performed. A crossover study was conducted in healthy subjects. The study was designed to compare the effects of different regimens of reversible CYP3A4 inhibitors, i.e., ketoconazole 400 mg OD, ketoconazole 200 mg BID, on two CYP3A4 substrates, alprazolam and midazolam, reflecting different pharmacokinetic properties in terms of first-pass effect and elimination. In parallel, time-based simulations were performed using the Simcyp population-based Simulator to address the usefulness of modeling to assess interaction clinical study design with CYP3A4 substrates. Comparison of the OD versus BID regimens for ketoconazole showed an opposite trend for the 2 substrates: BID (200 mg) dosing regimen provided the maximal clearance inhibition for alprazolam, while it was OD (400 mg) dosing regimen for midazolam. However, these effects are moderate despite the well-known pharmacokinetic differences between these substrates, suggesting that these differences are not enough. In the other way round, these investigations show how two CYP3A4 substrates can be different without leading to a major impact of the ketoconazole dosing regimen. The clinical findings are consistent with the Simcyp predictions, in particular the opposite trend observed with midazolam and alprazolam and the ketoconazole dosing regimen. These clinical investigations showed the influence of the CYP3A4 substrates' pharmacokinetic properties and the relevance of ketoconazole dose regimen on the magnitude of the interaction ratios. In addition, PBPK Simcyp simulations demonstrated how they can be used to help clinical study design assessment to capture the maximum effect.

Indexed as

AdolescentAdultAlprazolamCross-Over StudiesCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDose-Response Relationship, DrugDrug InteractionsHumansKetoconazoleMaleMidazolamSubstrate SpecificityYoung AdultAlprazolamCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsKetoconazoleMidazolamAlprazolamCYP3A4Drug–drug interactionKetoconazoleMidazolamPBPK simulation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.